Correlation of salivary cytokine IL-17A and 1,25 dihydroxycholecalciferol in patients undergoing orthodontic treatment.

The management of malocclusion has developed greatly in terms of treatment simulation and biomechanics, but treatment duration has been a great concern to the clinician as well as the patient. 1-25dihydroxycholecalciferol (biologically active form of Vitamin D) stimulates both osteoclasts and osteoblasts and was found to be the most significant in Orthodontic Tooth Movement acceleration. Inflammatory cytokines like IL-17A also play an important role in osteoclastogenesis and can enhance the rate of Orthodontic Tooth Movement.To perform a simultaneous evaluation of pro-inflammatory salivary cytokine IL-17A and salivary 1-25dihydroxycholecalciferol and to correlate their role on orthodontic tooth movement.A prospective cohort study was conducted among n = 97 patients. Saliva samples were collected from the patients at three phases of the orthodontic treatment, centrifuged and stored at 4℃ for evaluation of salivary 1-25dihydroxycholecalciferol levels and Pro-inflammatory cytokine IL-17A using ELISA.The mean salivary 1-25dihydoxycholecalciferol levels were 41.250 ng/ml, 33.246 ng/ml and 35.043 ng/ml during the initial phase, lag phase and post lag phase of orthodontic treatment. The mean pro-inflammatory cytokine IL-17 A levels were 107.79 pg/ml, 102.98 pg/ml and 66.156 pg/ml during the initial phase, lag phase and post lag phase of orthodontic treatment. There was a correlation between the salivary 1-25dihydroxycholecalciferol level and salivary cytokine IL-17A levels during the various phases of orthodontic treatment using Spearman's correlation rho test and linear regression analysis. There was no significant difference (p > 0.05) between 1-25dihydroxycholecalciferol levels and gender during the various phases (initial phase, lag phase and post lag phase) of Orthodontic treatment.There was a negative correlation between salivary 1-25dihydroxycholecalciferol level and salivary cytokine IL-17A levels during the various phases of orthodontic treatment. The level of 1-25dihydroxycholecalciferol and salivary cytokine IL-17A have been quantified during the various phases of Orthodontic treatment and this can be used clinically for the supplementation of Vitamin D in patients with low vitamin D levels and can enhance the treatment duration for the patient with less damaging effects to the surrounding tissues.

Salivary vitamin D levels among OSCC and normal Indian patients.

Oral Squamous Cell Carcinoma comprises nearly 90% of all Oral cancers. Recent studies on Oral Squamous Cell Carcinoma are done with a focus on identification of factors that affect the outcome of treatment, one of which is vitamin D levels. The aim of this study was to evaluate vitamin D3 levels in patients with Oral Squamous Cell Carcinoma and Normal Population with saliva as a biomarker. The study sample comprised of 40 subjects, of whom 20 were patients diagnosed with OSCC and 20 healthy subjects. The salivary samples obtained were assessed using Vitamin D3 ELISA kit. The mean salivary Vitamin D3 levels were 39.09 ng/dl among OSCC patients and 44.49 ng/dl among healthy subjects. Salivary Vitamin D levels in OSCC patients were found to be significantly less compared to the healthy controls. More than 90% of cancers of the oral cavity are Oral Squamous Cell Carcinoma (OSCC). Recent studies are done with a focus on identification of factors affecting the treatment of cancer, one of which is vitamin D levels. The aim of the study was to evaluate salivary vitamin D3 levels in patients with Oral Squamous Cell Carcinoma and in Normal Population. 40 patients were selected for the study. Salivary samples collected were assessed using Vitamin D3 ELISA Kit-EDI Total 25-OH Vitamin D EIA Kit to detect the salivary vitamin D levels. Mean Salivary Vitamin D3 levels were found to be 39.09 ng/dl in OSCC patients and 44.49 ng/dl in healthy subjects. A salivary Vitamin D level in OSCC patients was found to be significantly less compared to the healthy controls. Decreased Vitamin D3 levels in patients with OSCC indicate that Vitamin D3 deficiency increases the rate of cell proliferation, invasion, angiogenesis & metastasis in patients with OSCC. Vitamin D level is likely to reduce the severity of the disease and hence Vitamin D supplementation for OSCC patients in the early stages of treatment and after treatment can be done to enhance the prognosis.